Actively Recruiting

Phase Not Applicable
Age: 60Years - 85Years
All Genders
NCT04571918

Arthroscopic Treatment of Massive Rotator Cuff Tears With Debridement and Biodegradable Spacer.

Led by Oslo University Hospital · Updated on 2020-10-01

50

Participants Needed

2

Research Sites

460 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Massive rotator cuff tears are common in the adult population. It is estimated that about 12 % of adults 60 years of age or older suffer from a rotator cuff injury. About 40 % of these injuries are classified as massive rotator cuff tears (MRCT). MRCT propose a great challenge to the affected patient and its doctor. It is a painful condition with few treatment options. The study aims to investigate the operative treatment for MRCT with the new treatment option proposed by Senecovic. Insertion of a biodegradable balloon as a subacromial spacer has proven promising results so far. To this date there is only small and non-randomized studies on the subject. AMRIS are planning to do a randomized controlled study where group A is treated with arthroscopic debridement, biceps tenotomy and biodegradable spacer, while group B, the control group are treated with arthroscopic debridement and biceps tenotomy.

CONDITIONS

Official Title

Arthroscopic Treatment of Massive Rotator Cuff Tears With Debridement and Biodegradable Spacer.

Who Can Participate

Age: 60Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients suffering from a symptomatic massive rotator cuff tear, with fatty infiltration grade 3 or 4 classified on CT by Goutallier et al, or MRI by Fuchs classification.
  • Persistent pain for at least 3 months, with documented failure of conservative treatment
  • Age ranging from 60 years of age to 85 years of age
Not Eligible

You will not qualify if you...

  • Significant shoulder osteoarthritis in the affected shoulder, Hamada classification >2.
  • Total rupture of subscapularis tendon and/or teres minor, classified B and E in the Collins classification.
  • Comorbidity to the degree that the patient will not be able to participate in the follow up program.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Hospital of Southern Norway, Arendal

Arendal, Norway, 4848

Actively Recruiting

2

Oslo university hospital

Oslo, Norway, 0424

Not Yet Recruiting

Loading map...

Research Team

H

Hannah Ugletveit Jahr, Cand. med.

CONTACT

B

Berte Bøe, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here